Pepgen reports third quarter 2023 financial results and recent corporate developments

- continuing to open connect1-edo51 trial sites in canada - - opening of freedom-dm1 trial sites underway in the u.s. and canada - - ended third quarter 2023 with cash and cash equivalents of $129.5 million; cash runway expected into 2025 - boston, nov. 08, 2023 (globe newswire) -- pepgen inc. (nasdaq: pepg), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the third quarter ended september 30, 2023 and highlighted recent corporate developments. “we made significant progress across our pipeline of enhanced delivery oligonucleotide (edo) candidate therapeutics in the third quarter of 2023, including positive news from regulatory authorities that enable the launch of our freedom-dm1 study in the u.s. and canada,” said james mcarthur, ph.d.
PEPG Ratings Summary
PEPG Quant Ranking